Mangafodipir trisodium: effects on T2- and T1-weighted MR cholangiography.
The purpose of this study was to determine the effects of mangafodipir trisodium on heavily T2-weighted magnetic resonance cholangiography (MRC) images and on functional T1-weighted MRC. Pre- and post-mangafodipir trisodium heavily T2-weighted MRC and fat-suppressed T1-weighted three-dimensional (3D) gradient-echo MRC images were obtained in a patient with a prior cholecystectomy and a long cystic duct remnant that had apparent biliary stasis. Multiplanar reconstructed images were created. The precontrast T2-weighted MRC showed a long cystic duct remnant and a normal common bile duct (CBD). The postcontrast T2-weighted MRC showed loss of CBD signal, but persistent signal in the cystic duct remnant due to biliary stasis. Post-mangafodipir T1-weighted 3D gradient-echo images showed the main right and left hepatic ducts, but the cystic duct was not depicted. Conventional T2-weighted MRC sequences should not be obtained after administering mangafodipir trisodium because this contrast agent decreases the T2 and therefore the signal intensity of bile within normally functioning bile ducts. Functional MRC images can be acquired by using a post-mangafodipir T1-weighted technique.